B
etween ill health at one extreme and optimal health at the other on the health continuum exist at least 2 other categories: normal health (absence of disease) and absence of disease but "worried well." Many of the "worried well" may have illness anxiety disorder (IAD), a new term for what was formerly called hypochondriasis, and the subject of this article.
The etymology of the word hypochondria is hypokhondria, or under the cartilage (the breastplate), referring to the ancient Greek belief that the thoracic viscera were the source of melancholy, or sadness and worry. Hypochondria was used to mean depression, or melancholy without a real cause (1660) or illness without a specific cause (1839). Patients with IAD may not only have anxiety about health and disease in themselves but also in people around them. IAD patients may research the disease(s) they imagine they have, sometimes inducing what is commonly been referred to as "med student syndrome." They tend to overutilize health care services and undergo extensive medical care, invasive diagnostic procedures, and even unneeded elective surgeries.
Patients have an obsessional preoccupation with the idea that they are currently (or will be) experiencing a physical illness. Their preoccupation in usually centered on conditions such as cancer, HIV, AIDS, and so on. However, patients may fixate on any type of illness. Patients are convinced that harmless physical symptoms are indicators of serious disease or severe medical conditions. They frequently misinterpret physical symptoms of anxiety as signs of an impending physical health problem. Individuals with IAD usually do not see their concerns as being psychological in origin and thus may reject the suggestion that they consult a mental health professional.
Having a first-degree relative with IAD (through observational learning) is a risk factor for IAD as is a personal or family history of a serious/chronic illness or an experience with the medical profession that diminished trust or confidence in physicians. 3 Another risk factor is an major stressor or serious but eventually benign threat to the individual's health. Child abuse or serious illness in childhood is also a risk factor. 4 The differential diagnosis of IAD includes all of the following: It may be useful to think of IAD as an obsessive-compulsive disorder, an approach that was considered but not adopted during development of the DSM-5. 4 The Yale-Brown Obsessive-Compulsive Scale has been modified to assess hypochondriasis and may be used to make the diagnosis of IAD. 7 The Hypochondriasis Yale-Brown ObsessiveCompulsive Scale is the first clinicianadministered semistructured interview for IAD. 8 This interview seemed reliable and a valid addition to the assessment arsenal measuring IAD symptoms. A variety of self-report questionnaires are available to facilitate assessment of the severity of IAD, including the Illness Behavior Questionnaire, 9 Illness Attitudes Scale, 10 and Health Anxiety Inventory.
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Although the DSM-5 does not specify the prognosis or treatment for IAD, it may endure and persist for life, but is amenable to treatment. Treatment techniques used for anxiety disorders have greatly improved the prognosis for IAD. 4 The lifestyle medicine approach seems more suitable to the treatment of IAD than does the conventional medicine approach as the former treats the cause of the disease, is long term, and makes the patient an active partner in care 12 (see Table 1 ). In the absence of past trauma or conflict, the physician should talk to the IAD patient about exaggerated preoccupations with health. Those complaints should be taken seriously but the physician should acknowledge that the patient's preoccupation with physical symptoms is higher than normal, whether there is a medical diagnosis or not. Patients with IAD may initially resist the idea that their complaints are anything other than a nonpsychiatric medical illness. Motivational interviewing, which is often used in a lifestyle medicine approach to gauge a patient's willingness to change, may be used to assess readiness to accept mental health treatment. 13 This approach should be introduced early in treatment to increase motivation to change and weaken the patient's conviction regarding the presence of a feared illness. 4 The situation is not unlike that faced with fibromyalgia (FM) patients who, in the past, were often considered chronic complainers without a legitimate disease. We now know that many of them have a lower than normal pain threshold (demonstrated by functional magnetic resonance imaging), which helps explain why they have generalized, widespread chronic pain. 14 FM patients should now be told that they have have a decreased pain threshold. Their treatment involves teaching them how to redefine and reframe their pain. FM patients no longer need to spend years doctor shopping and undergoing multiple tests to rule out disease. They can be told they have FM, which is no longer a diagnosis of exclusion. Similarly, IAD is no longer a diagnosis of exclusion as the DSM-5 clearly delineates its positive symptoms. Few imaging studies on IAD exist but what data are available suggest that patients with IAD may have volumetric abnormalities in the orbital frontal cortex, thalamus, and pituitary. 15, 16 As with FM patients those with IAD no longer need to go through extensive and sometimes invasive workups to exclude multiple other diseases as IAD is now a recognized one with positive symptoms.
In most if not all cases of IAD, the patient's primary doctor should continue to play an important role. 5 Reasons for this the following: A number of empirically supported treatments have been developed for IAD. A coaching approach as advocated in the practice of lifestyle medicine may be more effective in the treatment of IAD opposed to the expert approach used in traditional medical care. 12 Mindfulnessbased stress reduction has been shown to result in enhanced psychological hardiness, lasting decreases in physical and psychological symptoms, increased ability to relax, and greater ability to cope with short-and long-term stressful situations. 17 Cognitive behavioral therapy (CBT) emphasizes the role of dysfunctional beliefs in maintaining illness anxiety and may be useful to instruct on how patients should respond to body signals. 18 Pharmacotherapy such as a selective serotonin reuptake inhibitor may also be useful. (There is an OCD component to the disorder, or it may be a form of OCD.) 19 The first randomized, controlled, double-blind trial comparing the efficacy of CBT, a selective serotonin reuptake inhibitor (paroxetine), and placebo in patients with IAD included 112 subjects and found that treatment with CBT resulted in better outcomes than treatment with paroxetine or placebo. (Response rates: CBT 45%; paroxetine 30%; placebo 14%.) The short-term effects (4 months) and the long-term effects (5 years) of both treatments were compared to each other and to the placebo. It was concluded that both are effective treatments for IAD compared to the placebo in the short term, but the significant differences between active treatments in ameliorating symptoms disappeared over time. CBT, however, was more effective in decreasing comorbid depressive and neurotic symptoms during the follow-up period than the placebo. Furthermore, CBT resulted in less use of additional psychological or medical help during the follow-up. 20 In summary, IAD, as defined by the DSM-5, should now be diagnosed in terms of positive symptoms. There are assessment tools to help in making the diagnosis of IAD and in assessing illness severity. A lifestyle medicine approach using motivational interviewing, mindfulness-based stress reduction, and CBT may be effective in IAD treatment.
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